Besides inhaled small‐molecule drugs, penetration of the mucus barrier is also a major hurdle for the development of inhaled nucleic acid‐based therapies (NABT) including mRNA replacement, DNA replacement and antisense oligonucleotides, as well as gene editing approaches, that are currently pursued to address the high unmet need of the remaining ∼10% of CF patients who are not eligible for CFTR modulators (Graeber & Mall, 2023). The gene discussed is CFTR; the disease is cystic fibrosis.